Fig. 4From: Development of an engineered peptide antagonist against periostin to overcome doxorubicin resistance in breast cancerWestern blot analysis for expression of pAKT and survivin. a-b Signal from immunodetection of pAkt, Akt, survivin and β-actin as the internal control. c-d Intensity of pAKT normalized by Akt expression. e-f Intensity of survivin normalized by β-actin expression. M = mock transfected, PN = PN-transfected, error bar determined SEM, * = P-value < 0.05 and n.s. = not significantBack to article page